Structural and functional differences between KRIT1A and KRIT1B isoforms: A framework for understanding CCM pathogenesis

Experimental Cell Research

Volumn 315, Issue 2, 2009, Pages 285-303

  Francalanci, Floriana ^a   Avolio, Maria ^a   De Luca, Elisa ^a   Longo, Dario ^c   Menchise, Valeria ^d   Guazzi, Paolo ^b   Sgrò, Francesco ^a   Marino, Marco ^a   Goitre, Luca ^a   Balzac, Fiorella ^a   Trabalzini, Lorenza ^b   Retta, Saverio Francesco ^a  

^a Biology and Biochemistry ^*  (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d CNR   (Italy)

Author keywords

CCM; FERM domain; Head to tail protein interaction; Homology modeling; ICAP1; KRIT1; Ligand docking; Nucleocytoplasmic shuttling; Rap1A; Yeast two hybrid interaction

Indexed keywords

CELL PROTEIN; PROTEIN KRIT1A; PROTEIN KRIT1B; RAP1 PROTEIN; RAP1A PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BRAIN MALFORMATION; CELLULAR DISTRIBUTION; CEREBRAL CAVERNOUS MALFORMATION; CONTROLLED STUDY; EXON; MOLECULAR MODEL; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TRANSPORT; SEQUENCE HOMOLOGY; STRUCTURE ACTIVITY RELATION;

EID: 57749178396     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2008.10.006     Document Type: Article

References (55)

1. Serebriiskii I., Estojak J., Sonoda G., Testa J.R., and Golemis E.A. Association of Krev-1/rap1a with Krit1, a novel ankyrin repeat-containing protein encoded by a gene mapping to 7q21-22. Oncogene 15 (1997) 1043-1049
2. Eerola I., McIntyre B., and Vikkula M. Identification of eight novel 5′-exons in cerebral capillary malformation gene-1 (CCM1) encoding KRIT1. Biochim. Biophys. Acta 1517 (2001) 464-467
3. Sahoo T., Goenaga-Diaz E., Serebriiskii I.G., Thomas J.W., Kotova E., Cuellar J.G., Peloquin J.M., Golemis E., Beitinjaneh F., Green E.D., Johnson E.W., and Marchuk D.A. Computational and experimental analyses reveal previously undetected coding exons of the KRIT1 (CCM1) gene. Genomics 71 (2001) 123-126
4. Zhang J., Clatterbuck R.E., Rigamonti D., and Dietz H.C. Cloning of the murine Krit1 cDNA reveals novel mammalian 5′ coding exons. Genomics 70 (2000) 392-395
5. Laberge-le Couteulx S., Jung H.H., Labauge P., Houtteville J.P., Lescoat C., Cecillon M., Marechal E., Joutel A., Bach J.F., and Tournier-Lasserve E. Truncating mutations in CCM1, encoding KRIT1, cause hereditary cavernous angiomas. Nat. Genet. 23 (1999) 189-193
6. Sahoo T., Johnson E.W., Thomas J.W., Kuehl P.M., Jones T.L., Dokken C.G., Touchman J.W., Gallione C.J., Lee-Lin S.Q., Kosofsky B., Kurth J.H., Louis D.N., Mettler G., Morrison L., Gil-Nagel A., Rich S.S., Zabramski J.M., Boguski M.S., Green E.D., and Marchuk D.A. Mutations in the gene encoding KRIT1, a Krev-1/rap1a binding protein, cause cerebral cavernous malformations (CCM1). Hum. Mol. Genet. 8 (1999) 2325-2333
7. Felbor U., Sure U., Grimm T., and Bertalanffy H. Genetics of cerebral cavernous angioma. Zentralbl. Neurochir. 67 (2006) 110-116
8. Labauge P., Denier C., Bergametti F., and Tournier-Lasserve E. Genetics of cavernous angiomas. Lancet Neurol. 6 (2007) 237-244
9. Whitehead K.J., Plummer N.W., Adams J.A., Marchuk D.A., and Li D.Y. Ccm1 is required for arterial morphogenesis: implications for the etiology of human cavernous malformations. Development 131 (2004) 1437-1448
10. Zawistowski J.S., Serebriiskii I.G., Lee M.F., Golemis E.A., and Marchuk D.A. KRIT1 association with the integrin-binding protein ICAP-1: a new direction in the elucidation of cerebral cavernous malformations (CCM1) pathogenesis. Hum. Mol. Genet. 11 (2002) 389-396
11. Zawistowski J.S., Stalheim L., Uhlik M.T., Abell A.N., Ancrile B.B., Johnson G.L., and Marchuk D.A. CCM1 and CCM2 protein interactions in cell signaling: implications for cerebral cavernous malformations pathogenesis. Hum. Mol. Genet. 14 (2005) 2521-2531
12. Zhang J., Clatterbuck R.E., Rigamonti D., Chang D.D., and Dietz H.C. Interaction between krit1 and icap1alpha infers perturbation of integrin beta1-mediated angiogenesis in the pathogenesis of cerebral cavernous malformation. Hum. Mol. Genet. 10 (2001) 2953-2960
13. Zhang J., Rigamonti D., Dietz H.C., and Clatterbuck R.E. Interaction between krit1 and malcavernin: implications for the pathogenesis of cerebral cavernous malformations. Neurosurgery 60 (2007) 353-359 discussion 359
14. Sedgwick S.G., and Smerdon S.J. The ankyrin repeat: a diversity of interactions on a common structural framework. Trends Biochem. Sci. 24 (1999) 311-316
15. Balzac F., Avolio M., Degani S., Kaverina I., Torti M., Silengo L., Small J.V., and Retta S.F. E-cadherin endocytosis regulates the activity of Rap1: a traffic light GTPase at the crossroads between cadherin and integrin function. J. Cell Sci. 118 (2005) 4765-4783
16. Retta S.F., Balzac F., and Avolio M. Rap1: a turnabout for the crosstalk between cadherins and integrins. Eur. J. Cell Biol. 85 (2006) 283-293
17. Glading A., Han J., Stockton R.A., and Ginsberg M.H. KRIT-1/CCM1 is a Rap1 effector that regulates endothelial cell cell junctions. J. Cell Biol. 179 (2007) 247-254
18. Beraud-Dufour S., Gautier R., Albiges-Rizo C., Chardin P., and Faurobert E. Krit 1 interactions with microtubules and membranes are regulated by Rap1 and integrin cytoplasmic domain associated protein-1. FEBS J. 274 (2007) 5518-5532
19. Pearson M.A., Reczek D., Bretscher A., and Karplus P.A. Structure of the ERM protein moesin reveals the FERM domain fold masked by an extended actin binding tail domain. Cell 101 (2000) 259-270
20. Ceccarelli D.F., Song H.K., Poy F., Schaller M.D., and Eck M.J. Crystal structure of the FERM domain of focal adhesion kinase. J. Biol. Chem. 281 (2006) 252-259
21. Garcia-Alvarez B., de Pereda J.M., Calderwood D.A., Ulmer T.S., Critchley D., Campbell I.D., Ginsberg M.H., and Liddington R.C. Structural determinants of integrin recognition by talin. Mol. Cell 11 (2003) 49-58
22. Hamada K., Shimizu T., Matsui T., Tsukita S., and Hakoshima T. Structural basis of the membrane-targeting and unmasking mechanisms of the radixin FERM domain. EMBO J. 19 (2000) 4449-4462
23. Han B.G., Nunomura W., Wu H., Mohandas N., and Jap B.K. Crystallization and preliminary X-ray crystallographic analysis of the 30 kDa membrane-binding domain of protein 4.1 from human erythrocytes. Acta Crystallogr. D. Biol. Crystallogr. 56 (2000) 187-188
24. Shimizu T., Seto A., Maita N., Hamada K., Tsukita S., and Hakoshima T. Structural basis for neurofibromatosis type 2. Crystal structure of the merlin FERM domain. J. Biol. Chem. 277 (2002) 10332-10336
25. Smith W.J., Nassar N., Bretscher A., Cerione R.A., and Karplus P.A. Structure of the active N-terminal domain of Ezrin. Conformational and mobility changes identify keystone interactions. J. Biol. Chem. 278 (2003) 4949-4956
26. Retta S.F., Avolio M., Francalanci F., Procida S., Balzac F., Degani S., Tarone G., and Silengo L. Identification of Krit1B: a novel alternative splicing isoform of cerebral cavernous malformation gene-1. Gene 325 (2004) 63-78
27. Cave-Riant F., Denier C., Labauge P., Cecillon M., Maciazek J., Joutel A., Laberge-Le Couteulx S., and Tournier-Lasserve E. Spectrum and expression analysis of KRIT1 mutations in 121 consecutive and unrelated patients with cerebral cavernous malformations. Eur. J. Hum. Genet. 10 (2002) 733-740
28. Stahl S., Gaetzner S., Voss K., Brackertz B., Schleider E., Surucu O., Kunze E., Netzer C., Korenke C., Finckh U., Habek M., Poljakovic Z., Elbracht M., Rudnik-Schoneborn S., Bertalanffy H., Sure U., and Felbor U. Novel CCM1, CCM2, and CCM3 mutations in patients with cerebral cavernous malformations: in-frame deletion in CCM2 prevents formation of a CCM1/CCM2/CCM3 protein complex. Human Mutat. 29 (2008) 709-717
29. Thompson J.D., Higgins D.G., and Gibson T.J. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 22 (1994) 4673-4680
30. Kang B.S., Cooper D.R., Devedjiev Y., Derewenda U., and Derewenda Z.S. The structure of the FERM domain of merlin, the neurofibromatosis type 2 gene product. Acta Crystallogr. D. Biol. Crystallogr. 58 (2002) 381-391
31. Sippl M.J. Recognition of errors in three-dimensional structures of proteins. Proteins 17 (1993) 355-362
32. Hooft R.W., Vriend G., Sander C., and Abola E.E. Errors in protein structures. Nature 381 (1996) 272
33. Cornell W.D., Cieplak P., Bayly C.I., Gould I.R., Merz K.M., Ferguson D.M., Spellmeyer D.C., Fox T., Caldwell J.W., and Kollman P.A. A second-generation force field for the simulation of proteins, nucleic acids, and organic molecules. J. Am. Chem. Soc. 117 (1995) 5179-5197
34. Halgren T.A. Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94. J. Comput. Chem. 17 (1996) 490-519
35. Hess B., Bekker H., Berendsen H.J.C., and Fraaije J.G.E.M. LINCS: a linear constraint solver for molecular simulations. J. Comput. Chem. 18 (1997) 1463-1472
36. Degani S., Balzac F., Brancaccio M., Guazzone S., Retta S.F., Silengo L., Eva A., and Tarone G. The integrin cytoplasmic domain-associated protein ICAP-1 binds and regulates Rho family GTPases during cell spreading. J. Cell Biol. 156 (2002) 377-387
37. Toby G.G., and Golemis E.A. Using the yeast interaction trap and other two-hybrid-based approaches to study protein-protein interactions. Methods 24 (2001) 201-217
38. Kelley L.A., MacCallum R.M., and Sternberg M.J. Enhanced genome annotation using structural profiles in the program 3D-PSSM. J. Mol. Biol. 299 (2000) 499-520
39. Forman-Kay J.D., and Pawson T. Diversity in protein recognition by PTB domains. Curr. Opin. Struct. Biol. 9 (1999) 690-695
40. Schlessinger J., and Lemmon M.A. SH2 and PTB domains in tyrosine kinase signaling. Sci. STKE. 2003 (2003) RE12
41. Uhlik M.T., Temple B., Bencharit S., Kimple A.J., Siderovski D.P., and Johnson G.L. Structural and evolutionary division of phosphotyrosine binding (PTB) domains. J. Mol. Biol. 345 (2005) 1-20
42. Yan K.S., Kuti M., and Zhou M.M. PTB or not PTB-that is the question. FEBS Lett. 513 (2002) 67-70
43. Huang L., Hofer F., Martin G.S., and Kim S.H. Structural basis for the interaction of Ras with RalGDS. Nat. Struct. Biol. 5 (1998) 422-426
44. Kiel C., Wohlgemuth S., Rousseau F., Schymkowitz J., Ferkinghoff-Borg J., Wittinghofer F., and Serrano L. Recognizing and defining true Ras binding domains II: in silico prediction based on homology modelling and energy calculations. J. Mol. Biol. 348 (2005) 759-775
45. Nassar N., Horn G., Herrmann C., Block C., Janknecht R., and Wittinghofer A. Ras/Rap effector specificity determined by charge reversal. Nat. Struct. Biol. 3 (1996) 723-729
46. Campbell S.J., Gold N.D., Jackson R.M., and Westhead D.R. Ligand binding: functional site location, similarity and docking. Curr. Opin. Struct. Biol. 13 (2003) 389-395
47. Calderwood D.A., Fujioka Y., de Pereda J.M., Garcia-Alvarez B., Nakamoto T., Margolis B., McGlade C.J., Liddington R.C., and Ginsberg M.H. Integrin beta cytoplasmic domain interactions with phosphotyrosine-binding domains: a structural prototype for diversity in integrin signaling. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 2272-2277
48. Aloy P., and Russell R.B. Structural systems biology: modelling protein interactions. Nat. Rev., Mol. Cell Biol. 7 (2006) 188-197
49. Bracken C., Iakoucheva L.M., Romero P.R., and Dunker A.K. Combining prediction, computation and experiment for the characterization of protein disorder. Curr. Opin. Struct. Biol. 14 (2004) 570-576
50. Pufall M.A., and Graves B.J. Autoinhibitory domains: modular effectors of cellular regulation. Annu. Rev. Cell Dev. Biol. 18 (2002) 421-462
51. Li Q., Nance M.R., Kulikauskas R., Nyberg K., Fehon R., Karplus P.A., Bretscher A., and Tesmer J.J. Self-masking in an intact ERM-merlin protein: an active role for the central alpha-helical domain. J. Mol. Biol. 365 (2007) 1446-1459
52. Bretscher A., Edwards K., and Fehon R.G. ERM proteins and merlin: integrators at the cell cortex. Nat. Rev., Mol. Cell Biol. 3 (2002) 586-599
53. Kressel M., and Schmucker B. Nucleocytoplasmic transfer of the NF2 tumor suppressor protein merlin is regulated by exon 2 and a CRM1-dependent nuclear export signal in exon 15. Hum. Mol. Genet. 11 (2002) 2269-2278
54. Luque C.M., and Correas I. A constitutive region is responsible for nuclear targeting of 4.1R: modulation by alternative sequences results in differential intracellular localization. J. Cell Sci. 113 Pt. 13 (2000) 2485-2495
55. Kaffman A., and O'Shea E.K. Regulation of nuclear localization: a key to a door. Annu. Rev. Cell Dev. Biol. 15 (1999) 291-339